1. Cox, J. H., Dietzschold, B. & Schneider, L. G. Rabies virus glycoprotein. II. Biological and serological characterization. Infect. Immun. 16, 754 (1977).
2. Winkler, W. G., Fashinell, T. R., Leffingwell, L., Howard, P. & Conomy, J. P. Airborne Rabies Transmission in a Laboratory Worker. JAMA 226, 1219–1221 (1973).
3. CONSTANTINE, D. G. Rabies transmission by nonbite route. Public Health Rep. 77, 287 (1962).
4. Helmick, C. G., Tauxe, R. V & Vernon, A. A. Is There a Risk to Contacts of Patients with Rabies? 9, 511–518.
5. Aramburo, A., Willoughby, R. E., Bollen, A. W., Glaser, C. A., Hsieh, C. J., Davis, S. L., Martin, K. W. & Roy-Burman, A. Failure of the Milwaukee Protocol in a Child With Rabies. Clin. Infect. Dis. 53, 572–574 (2011).
6. Willoughby, R. E., Tieves, K. S., Hoffman, G. M., Ghanayem, N. S., Amlie-Lefond, C. M., Schwabe, M. J., Chusid, M. J. & Rupprecht, C. E. brief report Survival after Treatment of Rabies with Induction of Coma. www.nejm.org (2005).
7. Hampson, K., Coudeville, L., Lembo, T., Sambo, M., Kieffer, A., Attlan, M., Barrat, J., Blanton, J. D., Briggs, D. J., Cleaveland, S., Costa, P., Freuling, C. M., Hiby, E., Knopf, L., Leanes, F., Meslin, F.-X., Metlin, A., Miranda, M. E., Müller, T., Nel, L. H., Recuenco, S., Rupprecht, C. E., Schumacher, C., Taylor, L., Vigilato, M. A. N., Zinsstag, J., Dushoff, J. Estimating the Global Burden of Endemic Canine Rabies. PLoS Negl. Trop. Dis. 9, e0003709 (2015).
8. Rabies. https://www.who.int/health-topics/rabies#tab=tab_1. (accessed on 8 October 2021)
9. Wilde, H., Tipkong, P. & Khawplod, P. Economic issues in postexposure rabies treatment. J. Travel Med. 6, 238–242 (1999).
10. Rabies vaccines: WHO position paper – April 2018 Wkly. Epidemiol. Rec. 93, 201–219 (2018).
11. Khawplod, P., Wilde, H., Tepsumethanon, S., Limusanno, S., Tantawichien, T., Chomchey, P., Ayuthaya, A. B. N. & Wangroonsarb, Y. Prospective immunogenicity study of multiple intradermal injections of rabies vaccine in an effort to obtain an early immune response without the use of immunoglobulin. Clin. Infect. Dis. 35, 1562–1565 (2002).
12. Warrell, M. J. Current rabies vaccines and prophylaxis schedules: preventing rabies before and after exposure. Travel Med. Infect. Dis. 10, 1–15 (2012).
13. Tenzin, Wangdi, K. & Ward, M. P. Human and animal rabies prevention and control cost in Bhutan, 2001–2008: The cost–benefit of dog rabies elimination. Vaccine 31, 260–270 (2012).
14. Hanlon, C. A., Kuzmin, I. V., Blanton, J. D., Weldon, W. C., Manangan, J. S. & Rupprecht, .,C. E. Efficacy of rabies biologics against new lyssaviruses from Eurasia. Virus Res. 111,44–54 (2005).
15. Kuzmin, I. V., Novella, I. S., Dietzgen, R. G., Padhi, A. & Rupprecht, C. E. The rhabdoviruses: Biodiversity, phylogenetics, and evolution. Infect. Genet. Evol. 9, 541–553 (2009).
16. Conzelmann, K.-K., Cox, J. H., Schneider, L. G. & Thiel, H.-J. Molecular Cloning and Complete Nucleotide Sequence 01 the Attenuated Rabies Virus SAD 819.
17. Tordo, N., Poch, O., Ermine, A., Keith, G. & Rougeon, F. Walking along the rabies genome: is the large G-L intergenic region a remnant gene? Proc. Natl. Acad. Sci. 83, 3914–3918 (1986).
18. Piccinotti, S. & Whelan, S. P. J. Rabies Internalizes into Primary Peripheral Neurons via Clathrin Coated Pits and Requires Fusion at the Cell Body. PLOS Pathog. 12, e1005753 (2016).
19. Gaudin, Y., Ruigrok, R. W. H., Knossow, M. & Flamand1, A. Low-pH Conformational Changes of Rabies Virus Glycoprotein and Their Role in Membrane Fusion. J. Virol. 67, 1365–1372 (1993).
20. Kelly, R. M. & Strick, P. L. Rabies as a transneuronal tracer of circuits in the central nervous system. J. Neurosci. Methods 103, 63–71 (2000).
21. Deinhardt, K., Reversi, A., Berninghausen, O., Hopkins, C. R. & Schiavo, G. Neurotrophins Redirect p75NTR from a clathrin-independent to a clathrin-dependent endocytic pathway coupled to axonal transport. Traffic 8, 1736–1749 (2007).
22. Mentis, G. Z., Gravell, M., Hamilton, R., Shneider, N. A., O’Donovan, M. J. & Schubert, M. Transduction of motor neurons and muscle fibers by intramuscular injection of HIV-1- based vectors pseudotyped with select rabies virus glycoproteins. J. Neurosci. Methods 157, 208–217 (2006).
23. Klingen, Y., Conzelmann, K.-K. & Finke, S. Double-Labeled Rabies Virus: Live Tracking of Enveloped Virus Transport. J. Virol. 82, 237–245 (2008).
24. Gaudin, Y., Ruigrok, R. W. H., Tuffereau, C., Knossow, M. & Flamand, A. Rabies virus glycoprotein is a trimer. Virology 182, 627–632 (1992).
25. Tuffereau, C., Bénéjean, J., Blondel, D., Kieffer, B. & Flamand, A. Low-affinity nerve- growth factor receptor (P75NTR) can serve as a receptor for rabies virus. EMBO J. 17, 7250 (1998).
26. Thoulouze, M.-I., Lafage, M., Schachner, M., Hartmann, U., Cremer, H. & Lafon, M. The neural cell adhesion molecule is a receptor for rabies virus. J. Virol. 72, 7181–7190 (1998).
27. Lentz, T. L., Burrage, T. G., Smith, A. L., Crick, J. & Tignor, G. H. Is the acetylcholine receptor a rabies virus receptor? Science (80-. ). 215, 182–184 (1982).
28. Wang, J., Wang, Z., Liu, R., Shuai, L., Wang, X., Luo, J., Wang, C., Chen, W., Wang, X., Ge, J., He, X., Wen, Z. & Bu, Z. Metabotropic glutamate receptor subtype 2 is a cellular receptor for rabies virus. PLoS Pathog. 14, (2018).
29. Gaudin, Y., Tuffereau, C., Sefretain, D., Knossow, M. & Flamand, A. Reversible conformational changes and fusion activity of rabies virus glycoprotein. J. Virol. 65, 4853– 4859 (1991).
30. Dietzschold, B., Wunner, W. H., Wiktor, T. J., Lopes, A. D., Lafon, M., Smith, C. L. & Koprowski, H. Characterization of an antigenic determinant of the glycoprotein that correlates with pathogenicity of rabies virus. Proc. Natl. Acad. Sci. U. S. A. 80, 70–74 (1983).
31. Dietzschold, B., Wiktor, T. J., Trojanowski, J. Q., Macfarlan, R. I., Wunner, W. H., Torres- Anjel, M. J. & Koprowski, H. Differences in cell-to-cell spread of pathogenic and apathogenic rabies virus in vivo and in vitro. J. Virol. 56, 12–18 (1985).
32. Yamada, K., Noguchi, K. & Nishizono, A. Efficient N-glycosylation at position 37, but not at position 146, in the street rabies virus glycoprotein reduces pathogenicity. Virus Res. 179, 169–176 (2014).
33. Takayama-Ito, M., Ito, N., Yamada, K., Sugiyama, M. & Minamoto, N. Multiple amino acids in the glycoprotein of rabies virus are responsible for pathogenicity in adult mice. Virus Res. 115, 169–175 (2006).
34. Takayama-Ito, M., Inoue, K. ichi, Shoji, Y., Inoue, S., Iijima, T., Sakai, T., Kurane, I. & Morimoto, K. A highly attenuated rabies virus HEP-Flury strain reverts to virulent by single amino acid substitution to arginine at position 333 in glycoprotein. Virus Res. 119, 208–215 (2006).
35. Faber, M., Faber, M.-L., Papaneri, A., Bette, M., Weihe, E., Dietzschold, B. & Schnell, M. J. A Single Amino Acid Change in Rabies Virus Glycoprotein Increases Virus Spread and Enhances Virus Pathogenicity. J. Virol. 79, 14141 (2005).
36. Luo, J., Zhang, B., Wu, Y. & Guo, X. Amino Acid Mutation in Position 349 of Glycoprotein Affect the Pathogenicity of Rabies Virus. Front. Microbiol. 11, 481 (2020).
37. Faber, M., Pulmanausahakul, R., Hodawadekar, S. S., Spitsin, S., McGettigan, J. P., Schnell, M. J. & Dietzschold, B. Overexpression of the Rabies Virus Glycoprotein Results in Enhancement of Apoptosis and Antiviral Immune Response. J. Virol. 76, 3374 (2002).
38. Morimoto, K., Hooper, D. C., Spitsin, S., Koprowski, H. & Dietzschold, B. Pathogenicity of different rabies virus variants inversely correlates with apoptosis and rabies virus glycoprotein expression in infected primary neuron cultures. J. Virol. 73, 510–518 (1999).
39. Nigg, A. J. & Walker, P. L. Overview, prevention, and treatment of rabies. Pharmacotherapy 29, 1182–1195 (2009).
40. Both, L., Banyard, A. C., van Dolleweerd, C., Horton, D. L., Ma, J. K. C. & Fooks, A. R. Passive immunity in the prevention of rabies. Lancet Infect. Dis. 12, 397–407 (2012).
41. O’Brien, K. L., Nolan, T. & Rabies, on behalf of the S. W. on. The WHO position on rabies immunization – 2018 updates. Vaccine 37, A85 (2019).
42. Sparrow, E., Torvaldsen, S., Newall, A. T., Wood, J. G., Sheikh, M., Kieny, M. P. & Abela-Ridder, B. Recent advances in the development of monoclonal antibodies for rabies post exposure prophylaxis: A review of the current status of the clinical development pipeline. Vaccine 37, A132–A139 (2019).
43. Chao, T.-Y., Ren, S., Shen, E., Moore, S., Zhang, S., Chen, L., Rupprecht, C. E. & Tsao, E. SYN023, a novel humanized monoclonal antibody cocktail, for post-exposure prophylaxis of rabies. PLoS Negl. Trop. Dis. 11, e0006133 (2017).
44. Bakker, A. B. H., Python, C., Kissling, C. J., Pandya, P., Marissen, W. E., Brink, M. F., Lagerwerf, F., Worst, S., van Corven, E., Kostense, S., Hartmann, K., Weverling, G. J., Uytdehaag, F., Herzog, C., Briggs, D. J., Rupprecht, C. E., Grimaldi, R. & Goudsmit, J. First administration to humans of a monoclonal antibody cocktail against rabies virus: Safety, tolerability, and neutralizing activity. Vaccine 26, 5922–5927 (2008).
45. Yang, F., Lin, S., Ye, F., Yang, J., Qi, J., Chen, Z., Lin, X., Wang, J., Yue, D., Cheng, Y.Chen, Z., Chen, H., You, Y., Zhang, Z., Yang, Y., Yang, M., Sun, H., Li, Y., Cao, Y., Yang, S., Wei, Y., Gao, G. F., Lu, G. Structural Analysis of Rabies Virus Glycoprotein Reveals pH-Dependent Conformational Changes and Interactions with a Neutralizing Antibody. Cell Host Microbe 27, 441-453.e7 (2020).
46. Roche, S., Bressanelli, S., Rey, F. A. & Gaudin, Y. Crystal structure of the low-pH form of the vesicular stomatitis virus glycoprotein G. Science 313, 187–191 (2006).
47. Roche, S., Rey, F. A., Gaudin, Y. & Bressanelli, S. Structure of the Prefusion Form of the Vesicular Stomatitis Virus Glycoprotein G. Science (80-. ). 315, 843–848 (2007).
48. Harrison, S. C. Viral membrane fusion. Nat. Struct. Mol. Biol. 2008 157 15, 690–698(2008).
49. Hellert, J., Buchrieser, J., Larrous, F., Minola, A., de Melo, G. D., Soriaga, L., England, P., Haouz, A., Telenti, A., Schwartz, O., Corti, D., Bourhy, H. & Rey, F. A. Structure of the prefusion-locking broadly neutralizing antibody RVC20 bound to the rabies virus glycoprotein. Nat. Commun. 11, 1–8 (2020).
50. Meier, S., Güthe, S., Kiefhaber, T. & Grzesiek, S. Foldon, the natural trimerization domain of T4 fibritin, dissociates into a monomeric A-state form containing a stable β- hairpin: Atomic details of trimer dissociation and local β-hairpin stability from residual dipolar couplings. J. Mol. Biol. 344, 1051–1069 (2004).
51. Sissoëff, L., Mousli, M., England, P. & Tuffereau, C. Stable trimerization of recombinant rabies virus glycoprotein ectodomain is required for interaction with the p75NTRreceptor. J. Gen. Virol. 86, 2543–2552 (2005).
52. Passmore, L. A. & Russo, C. J. Specimen Preparation for High-Resolution Cryo-EM. Methods in Enzymology vol. 579 (Elsevier Inc., 2016).
53. Dessau, M. A. & Modis, Y. Protein Crystallization for X-ray Crystallography. J. Vis. Exp.(2011) doi:10.3791/2285.
54. Maeda, S., Kawai, T., Obinata, M., Fujiwara, H., Horiuchi, T., Saeki, Y., Sato, Y. & Furusawa, M. Production of human α-interferon in silkworm using a baculovirus vector. Nat. 1985 3156020 315, 592–594 (1985).
55. Luo, T. R., Minamoto, N., Hishida, M., Yamamoto, K., Fujise, T., Hiraga, S., Ito, N., Sugiyama, M. & Kinjo, T. Antigenic and functional analyses of glycoprotein of rabies virus using monoclonal antibodies. Microbiol. Immunol. 42, 187–193 (1998).
56. Luo, T. R., Minamoto, N., Ito, H., Goto, H., Hiraga, S., Ito, N., Sugiyama, M. & Kinjo, T. A virus-neutralizing epitope on the glycoprotein of rabies virus that contains Trp251 is a linear epitope. Virus Res. 51, 35–41 (1997).
57. Bühler, P., Wetterauer, D., Gierschner, D., Wetterauer, U., Beile, U. E. & Wolf, P. Influence of structural variations on biological activity of anti-PSMA scFv and immunotoxins targeting prostate cancer. Anticancer Res. 30, 3373–3379 (2010).
58. Kim, Y. J., Neelamegam, R., Heo, M. A., Edwardraja, S., Paik, H. J. & Lee, S. G. Improving the productivity of single-chain Fv antibody against c-Met by rearranging the order of its variable domains. J. Microbiol. Biotechnol. 18, 1186–1190 (2008).
59. Shiroishi, M., Tsumoto, K., Amano, K., Shirakihara, Y., Colonna, M., Braud, V. M., AllanD. S. J., Makadzange, A., Rowland-Jones, S., Willcox, B., Jones, E. Y., Merwe, P. A. van der, Kumagai, I. & Maenaka, K. Human inhibitory receptors Ig-like transcript 2 (ILT2) and ILT4 compete with CD8 for MHC class I binding and bind preferentially to HLA-G. Proc. Natl. Acad. Sci. 100, 8856–8861 (2003).
60. Glaeser, R. M. & Han, B.-G. Opinion: hazards faced by macromolecules when confined to thin aqueous films. Biophys. Reports 3, 1–7 (2017).
61. Postel, C., Abillon, O. & Desbat, B. Structure and denaturation of adsorbed lysozyme at the air–water interface. J. Colloid Interface Sci. 266, 74–81 (2003).
62. Taylor, K. A. & Glaeser, R. M. Retrospective on the early development of cryoelectron microscopy of macromolecules and a prospective on opportunities for the future. J. Struct. Biol. 163, 214–223 (2008).
63. Glaeser, R. M., Han, B. G., Csencsits, R., Killilea, A., Pulk, A. & Cate, J. H. D. Factors that Influence the Formation and Stability of Thin, Cryo-EM Specimens. Biophys. J. 110, 749–755 (2016).
64. Scheres, S. H. W. RELION: Implementation of a Bayesian approach to cryo-EM structure determination. J. Struct. Biol. 180, 519–530 (2012).
65. Zhang, K., Li, S., Kappel, K., Pintilie, G., Su, Z., Mou, T. C., Schmid, M. F., Das, R. & Chiu, W. Cryo-EM structure of a 40 kDa SAM-IV riboswitch RNA at 3.7 Å resolution. Nat. Commun. 2019 101 10, 1–6 (2019).
66. Puri, A., Winick, J., Lowy, R. J., Covell, D., Eidelman, O., Walter, A. & Blumenthal, R. Activation of vesicular stomatitis virus fusion with cells by pretreatment at low pH. J. Biol. Chem. 263, 4749–4753 (1988).
67. Matlin, J. & Helenius, K. Physical Properties of a Soluble Form of the Glycoprotein of Vesicular Stomatitis Virus at Neutral and Acidic pH1". J. Cell Biol 22, 674–679 (1983).
68. Bakker, A. B. H., Marissen, W. E., Kramer, R. A., Rice, A. B., Weldon, W. C., Niezgoda, M., Hanlon, C. A., Thijsse, S., Backus, H. H. J., de Kruif, J., Dietzschold, B., Rupprecht, C. E. & Goudsmit, J. Novel Human Monoclonal Antibody Combination Effectively Neutralizing Natural Rabies Virus Variants and Individual In Vitro Escape Mutants. J. Virol. 79, 9062–9068 (2005).
69. Melo, G. D. de, Sonthonnax, F., Lepousez, G., Jouvion, G., Minola, A., Zatta, F., Larrous, F., Kergoat, L., Mazo, C., Moigneu, C., Aiello, R., Salomoni, A., Brisebard, E., BenedictisP. De, Corti, D. & Bourhy, H. A combination of two human monoclonal antibodies cures symptomatic rabies. EMBO Mol. Med. 12, e12628 (2020).
70. Stark, H. GraFix: Stabilization of fragile macromolecular complexes for single particle Cryo-EM. Methods in Enzymology vol. 481 (Elsevier Inc., 2010).
71. Hauer, F., Gerle, C., Fischer, N., Oshima, A., Shinzawa-Itoh, K., Shimada, S., Yokoyama, K., Fujiyoshi, Y. & Stark, H. GraDeR: Membrane Protein Complex Preparation for Single- Particle Cryo-EM. Structure 23, 1769–1775 (2015).
72. Callaway, H. M., Zyla, D., Hastie, K. M., Avalos, R. D., Agarwal, A., Bourhy, H., Corti, D. & Saphire, E. O. Structure of the rabies virus glycoprotein trimer bound to a pre-fusion specific neutralizing antibody. bioRxiv 2021.11.16.468852 (2021) doi:10.1101/2021.11.16.468852.
73. Sumino, A., Uchihashi, T. & Oiki, S. Oriented Reconstitution of the Full-Length KcsA Potassium Channel in a Lipid Bilayer for AFM Imaging. J. Phys. Chem. Lett. 8, 785–793 (2017).
74. Sumino, A., Sumikama, T., Uchihashi, T. & Oiki, S. High-speed AFM reveals accelerated binding of agitoxin-2 to a K+ channel by induced fit. Sci. Adv. 5, eaax0495 (2019).
75. Hsieh, C. L., Goldsmith, J. A., Schaub, J. M., DiVenere, A. M., Kuo, H. C., Javanmardi, K.Le, K. C., Wrapp, D., Lee, A. G., Liu, Y., Chou, C. W., Byrne, P. O., Hjorth, C. K., JohnsonN. V., Ludes-Meyers, J., Nguyen, A. W., Park, J., Wang, N., Amengor, D., Lavinder, J. J., Ippolito G. C., Maynard J. A., Finkelstein I. J., McLellan J. S. Structure-based design of prefusion-stabilized SARS-CoV-2 spikes. Science (80-. ). 369, 1501–1505 (2020).
76. Sanders, R. W., Derking, R., Cupo, A., Julien, J. P., Yasmeen, A., de Val, N., Kim, H. J., Blattner, C., de la Peña, A. T., Korzun, J., Golabek, M., de los Reyes, K., Ketas, T. J., van Gils, M. J., King, C. R., Wilson, I. A., Ward, A. B., Klasse, P. J. & Moore, J. P. A Next- Generation Cleaved, Soluble HIV-1 Env Trimer, BG505 SOSIP.664 gp140, Expresses Multiple Epitopes for Broadly Neutralizing but Not Non-Neutralizing Antibodies. PLOS Pathog. 9, e1003618 (2013).
論文の公開元へ
